About us
Services
Quality Assurance
Supply Chain,
Warehousing & Distribution
Regulatory, Safety & Compliance
Sales & Customer Care Service
Marketing & Promotion Department
Products
Pharmaceutical
Laboratory &
Parapharmaceutical
Cosmeceutical
Careers
Contact us
Adverse Event
1. Seriousness assessment
Serious Adverse Event (SAE)
Yes
No
2. Initial adverse event (AE) or a follow-up report?
Initial
Follow-up
3. Patient
Sex
Male
Female
Date of birth or age
Name or Initials
Phone
Fax
Email
Ethicity/Race
Address
Weight
kg
Height
m
cm
Pregnant
Yes
No
If this is a
pregnancy observation
, please fill in a
Pregnancy Form
4. Suspected drug
Product
Lot / batch no
Expiry date
Formulation and strength
Total daily dose/dose+ frequency
Route (e.g. oral)
Duration of therapy
Indication for use of suspected drug
5. Adverse event
Main diagnosis/syndrome
Start date
Stop date
Overall Outcome
Recoverd
Recovering
Not Recoverd
Recovered w/sequelae
Fatal
Unknown
Causality
Possible related
Not related
Severity
Mild
Moderate
Severe
If patient died, cause of death
Autopsy report
Yes
No
If patient
recovered with sequelae
, please specify
6. If AE is serious, please tick all appropriate to AE(s)
Fatal
Life-threatening
In-patient hospitalisation
Prolongation of existing hospitalisation
Persistent or significant disability/incapacity
A congenital anomaly/birth defect
Other medically important condition
7. Date of hospitalisation
8. Date of discharge
9. Description of AE(s)
Diagnosis, signs, symptoms, course of event(s), drugs used for treatment and other examinations/treatments performed.
10. Dechallenge and rechallenge for suspected drug
Was treatment with product stopped due to the event(s)?
Yes
No
N/A
Did reaction(s) stop after discontinuing the drug?
Yes
No
N/A
Did reaction(s) reappear after reintroduction of the drug?
Yes
No
N/A
11. Has the patient previously been exposed to the suspected drug?
Unknown
No
Yes
Did any AE(s) occur then?
No
Yes
If yes, which AE
12. Concomitant medication:
None
Drug(s)
Formulation and strength
Total daily dose/ dose+ frequency
Formulation and strength
Route(e.g. oral)
Duration of therapy
Indication for use of concomitant drug
13. Are any of the concomitant medications suspected of being causally related to the AE?
No
Yes
Did the AE disappear after stop of drug?
Yes
No
N/A
Did the AE reappear after restart of drug?
Yes
No
N/A
14. Relevant medical history: (e.g. previous diagnoses, surgery, allergies)
Disease, surgical procedure, etc.
Start date
Continuing:(Y/N/Unknown)
End date
Comments
15. Relevant clinical/laboratory assessments
None
Attached
See below
Test(s)
Assessment date
Results
Unit
16. Reporter
Reporter’s name
Institution
Address
Date
Profession
Physician
Pharmacist
Nurse
Other Health Care Professional
Consumer
Country
Phone
Fax
Email
17. May the reporter be contacted again if necessary
Yes
No
Submit